Q1 EPS Forecast for vTv Therapeutics Increased by Analyst

vTv Therapeutics Inc. (NASDAQ:VTVT) – Research analysts at HC Wainwright raised their Q1 2026 EPS estimates for vTv Therapeutics in a research note issued on Monday, February 2nd. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings per share of $0.96 for the quarter, up from their previous estimate of ($0.70). HC Wainwright currently has a “Buy” rating and a $47.00 price objective on the stock. HC Wainwright also issued estimates for vTv Therapeutics’ Q4 2026 earnings at ($0.79) EPS, FY2026 earnings at ($1.28) EPS, FY2027 earnings at ($3.93) EPS, FY2028 earnings at ($3.02) EPS, FY2029 earnings at ($2.25) EPS and FY2030 earnings at ($1.67) EPS.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11).

Several other research firms also recently weighed in on VTVT. TD Cowen started coverage on shares of vTv Therapeutics in a report on Monday, January 5th. They issued a “buy” rating for the company. Wall Street Zen raised shares of vTv Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Roth Mkm started coverage on vTv Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $58.00 target price on the stock. Finally, BTIG Research restated a “buy” rating and issued a $49.00 target price (up from $40.00) on shares of vTv Therapeutics in a research report on Tuesday, January 27th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $55.25.

vTv Therapeutics Stock Performance

NASDAQ:VTVT opened at $36.41 on Wednesday. The stock has a market cap of $143.46 million, a price-to-earnings ratio of -10.97 and a beta of 0.50. vTv Therapeutics has a 1 year low of $14.00 and a 1 year high of $44.00. The business has a fifty day moving average of $35.01 and a 200-day moving average of $25.71.

Hedge Funds Weigh In On vTv Therapeutics

An institutional investor recently raised its position in vTv Therapeutics stock. Baker BROS. Advisors LP increased its position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,314 shares of the biotechnology company’s stock after acquiring an additional 51,000 shares during the quarter. Baker BROS. Advisors LP owned 3.77% of vTv Therapeutics worth $3,463,000 as of its most recent SEC filing. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.